RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announces the publication of studies in two peer-reviewed journals that support the use of metabolomics in the diagnosis and treatment of kidney cancer. The studies were conducted by Robert Weiss, M.D. of the Cancer Center at the University of California Davis and colleagues at the University’s Departments of Public Health Sciences and Internal Medicine in collaboration with Metabolon scientists.
